1-12 of 12
Delphine Rea, MDPhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

ETNK1 Mutations in Atypical Chronic Myeloid Leukemia Induce a Mutator Phenotype That Can be Reverted with Phosphoethanolamine

Diletta Fontana, PhD, Mario Mauri, PhD, Rossella Renso, MD, Mattia Docci, MD, Ilaria Crespiatico, MS, Lisa M Røst, PhD, Mi Jang, PhD, Antonio Niro, MS, Deborah D'Aliberti, PhD, Luca Massimino, PhD, Mayla Bertagna, MS, Giovanni Zambrotta, MD, Mario Bossi, MS, Stefania Citterio, MS, Barbara Crescenzi, PhD, Francesca Fanelli, PhD, Valeria Cassina, PhD, Roberta Corti, PhD, Domenico Salerno, PhD, Luca Nardo, PhD, Clizia Chinello, PhD, Francesco Mantegazza, PhD, Cristina Mecucci, MD PhD, Fulvio Magni, PhD, Guido Cavaletti, MD, Per Bruheim, PhD, Delphine Rea, MDPhD, Steen Larsen, PhD, Rocco Piazza, MD PhD, Carlo Gambacorti-Passerini, MD
Journal: Blood
Blood (2020) 136 (Supplement_2): LBA-5.
https://doi.org/10.1182/blood-2020-143852
Published: 2020
Journal Articles

Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs

Andreas Hochhaus, MD, Carla Boquimpani, MD, Delphine Rea, MDPhD, Yosuke Minami, MDPhD, Elza Lomaia, MD PhD, Sergey Voloshin, MD PhD, Anna G. Turkina, Prof., MD, Dong-Wook Kim, MD, Jane Apperley, FRCP, FRCPath, MB, Jorge E. Cortes, MD, Andre Abdo, MD, Laura Maria Fogliatto, MD PhD, Dennis Dong Hwan Kim, MD PhD, Philipp D le Coutre, MD, Susanne Saussele, MD, Mario Annunziata, MD, Timothy P. Hughes, MDMBBS,FRACP,FRCPA, Naeem A. Chaudhri, MD, Lynette C.Y. Chee, MBBS,PhDFRACP,FRCPA, Valentín García Gutiérrez, MD PhD, Koji Sasaki, MD, Paola Aimone, MD, Alex Allepuz, MD MPH, Sarah Quenet, Véronique Bédoucha, Michael J. Mauro, MD
Journal: Blood
Blood (2020) 136 (Supplement_2): LBA-4.
https://doi.org/10.1182/blood-2020-143816
Published: 2020
Journal Articles

Myeloid Blast Crisis of Philadelphia Positive Chronic Myeloid Leukemia and Philadelphia Positive Acute Myeloid Leukemia Treated at the AP-HP in Paris: A Retrospective Analysis

Matteo Dragani, MD, Rathana Kim, PharmD, Clémence Loiseau, MD, Madalina Uzunov, MD, Felipe Suarez, MDPhD, Didier Bouscary, MDPhD, Philippe Rousselot, MDPhD, Etienne Lengline, MD, Raphael Itzykson, MD PhD, Jean Michel Cayuela, PhD, Nicolas Boissel, MD PhD, Herve Dombret, MD PhD, Delphine Rea, MDPhD, Emmanuel Raffoux, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 35–36.
https://doi.org/10.1182/blood-2020-140998
Published: 2020
Journal Articles

NFE2 Mutations Impact AML Transformation and Overall Survival in Patients with Myeloproliferative Neoplasms (MPN)

Clemence Marcault, MD, Lin-Pierre Zhao, MD, Rafael Daltro De Oliveira, MD, Juliette Soret, MD, Nicolas Gauthier, MD, Emmanuelle Verger, PhD, Nabih Maslah, PharmD, Blandine Roux, MSc, Nathalie Parquet, MD, Christine Dosquet, MD, Delphine Rea, MDPhD, Jean-Marc Zini, William Vainchenker, Emmanuel Raffoux, MD, Stephane Giraudier, MD PhD, Bruno Cassinat, PharmD, PhD, Jean-Jacques Kiladjian, Lina Benajiba, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 36.
https://doi.org/10.1182/blood-2020-136177
Published: 2020
Journal Articles

Long-Term Outcome of Chronic Phase Chronic Myeloid Leukemia Patients Treated with Nilotinib Front-Line

Franck E Nicolini, MDPhD, Vincent Alcazer, MD, Pascale Cony-Makhoul, MD, Stephanie Dulucq, PharmD, PhD, Sandrine Hayette, PhD, Stephane Morisset, BioStat, Jean-Michel Cayuela, PharmD, PhD, Marie-Pierre Fort, PhD, Christophe Bouvier, CRA, Clemence Deteix-Santana, MD, Etienne Lengline, MD, Delphine Rea, MDPhD, Francois-Xavier Mahon, MD PhD, Gabriel Etienne, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 44–45.
https://doi.org/10.1182/blood-2020-139921
Published: 2020
Journal Articles

Ruxolitinib Treatment Is Associated with Increased Incidence of Infections and Higher Risk of HSV/Vzv Recurrence in Patients with Myeloproliferative Neoplasm (MPN) Related Myelofibrosis (MF)

Nicolas Gauthier, MD, Juliette Soret-Dulphy, MD, Lin-Pierre Zhao, MD, Rafael Daltro De Oliveira, MD, Clemence Marcault, MD, Nathalie Parquet, MD, Jean-Marc Zini, Delphine Rea, MDPhD, Emmanuel Raffoux, MD, Bruno Cassinat, PharmD, PhD, Stephane Giraudier, MD PhD, Jean-Jacques Kiladjian, Lina Benajiba, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 8.
https://doi.org/10.1182/blood-2020-141260
Published: 2020
Journal Articles

Efficacy and Safety of Ponatinib (PON) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Who Failed One or More Second-Generation (2G) Tyrosine Kinase Inhibitors (TKIs): Analyses Based on PACE and Optic

Hagop M. Kantarjian, MD, Michael W. Deininger, MD PhD, Elisabetta Abruzzese, MD, Jane Apperley, FRCP, FRCPath, MB, Jorge E. Cortes, MD, Charles Chuah, MD, Daniel J. DeAngelo, MD PhD, John F. DiPersio, MD PhD, Andreas Hochhaus, MD, Jeffrey H. Lipton, MD PhD, Franck E Nicolini, MDPhD, Javier Pinilla Ibarz, MD PhD, Delphine Rea, MDPhD, Gianantonio Rosti, MD, Philippe Rousselot, MDPhD, Neil P Shah, MD PhD, Moshe Talpaz, MD, Shouryadeep Srivastava, MBBS, PhD, Vickie Lu, PhD, Michael J. Mauro, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 43–44.
https://doi.org/10.1182/blood-2020-133922
Published: 2020
Journal Articles

COVID-19 in Patients (pts) with Chronic Myeloid Leukemia (CML): Results from the International CML Foundation (iCMLf) CML and COVID-19 (CANDID) Study

Delphine Rea, MDPhD, Michael J. Mauro, MD, Jorge E. Cortes, MD, Qian Jiang, MD, Katia B Pagnano, MDPhD, Matilda Ongondi, MD, Chung Hoow Kok, BSc, PhD, Nicola Evans, Timothy P. Hughes, MDMBBS,FRACP,FRCPA, International CML Foundation
Journal: Blood
Blood (2020) 136 (Supplement 1): 46–47.
https://doi.org/10.1182/blood-2020-140161
Published: 2020
Journal Articles

Asciminib, a First-in-Class STAMP Inhibitor, Provides Durable Molecular Response in Patients (pts) with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: Primary Efficacy and Safety Results from a Phase 1 Trial

Jorge E. Cortes, MD, Timothy P. Hughes, MDMBBS,FRACP,FRCPA, Michael J. Mauro, MD, Andreas Hochhaus, MD, Delphine Rea, MDPhD, Yeow Tee Goh, MBBS, Jeroen Janssen, Juan Luis Steegmann, Michael C. Heinrich, MD, Moshe Talpaz, MD, Gabriel Etienne, MD PhD, Massimo Breccia, MD, Michael W. Deininger, MD PhD, Philipp D le Coutre, MD, Fabian Lang, MD, Paola Aimone, MD, Fotis Polydoros, Silvia Cacciatore, Laura Stenson, Dong-Wook Kim, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 47–50.
https://doi.org/10.1182/blood-2020-139677
Published: 2020
Journal Articles

SF3B1 mutations in the Driver Clone Increase the Risk of Evolution to Myelofibrosis in Patients with Myeloproliferative Neoplasms (MPN)

Lin-Pierre Zhao, MD, Rafael Daltro De Oliveira, MD, Clemence Marcault, MD, Juliette Soret, MD, Nicolas Gauthier, MD, Emmanuelle Verger, PhD, Nabih Maslah, PharmD, Blandine Roux, MSc, Nathalie Parquet, MD, Christine Dosquet, MD, Delphine Rea, MDPhD, Jean-Marc Zini, MD, William Vainchenker, Emmanuel Raffoux, MD, Stephane Giraudier, MD PhD, Bruno Cassinat, PharmD, PhD, Jean-Jacques Kiladjian, MD PhD, Lina Benajiba, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 1.
https://doi.org/10.1182/blood-2020-141296
Published: 2020
Journal Articles

Evidence of ETNK1 Somatic Variants in Atypical Chronic Myeloid Leukemia

Carla Donadoni, PhD, Rocco Piazza, MD PhD, Diletta Fontana, M.Sc., Andrea Parmiani, M.Sc., Alessandra Pirola, M.Sc., Sara Redaelli, PhD, Giovanni Signore, M.Sc., Vincenzo Piazza, PhD, Luca Malcovati, MD, Roberta Spinelli, M.Sc., Vera Magistroni, PhD, Giuseppe Gaipa, Marco Peronaci, M.Sc., Alessandro Morotti, MDPhD, Cristina Panuzzo, PhD, Giuseppe Saglio, MD, Elena Maria Elli, MD, Emilio Usala, MD, Dong-Wook Kim, MD PhD, Delphine Rea, MDPhD, Konstantinos Zervakis, MD, Nora-Athina Viniou, MD, Argiris Symeonidis, MD, Heiko Becker, MD, Jacqueline Boultwood, PhD, Leonardo Campiotti, MD, Matteo G Carrabba, MD, Graham R Bignell, PhD, Elli Papaemmanuil, PhD, Peter J Campbell, PhD, Mario Cazzola, MD, Carlo Gambacorti-Passerini, MD
Journal: Blood
Blood (2014) 124 (21): 2212.
https://doi.org/10.1182/blood.V124.21.2212.2212
Published: 2014
Journal Articles

Imatinib Mesylate Dose Escalation Improves Disease Response in Chronic-Phase Chronic Myeloid Leukaemia Patients after Cytogenetic or Molecular Suboptimal Responses to Standard Doses of Imatinib.

Delphine Rea, MDPhD, Gabriel Etienne, MD, Selim Corm, MD, Pascale Cony-Makhoul, MD, Martine Gardembas, MD, Francois-Xavier Mahon, MDPhD, Franck Nicolini, MDPhD
Journal: Blood
Blood (2007) 110 (11): 1052.
https://doi.org/10.1182/blood.V110.11.1052.1052
Published: 2007